Abstract:Unlike many other diagnostic tests, a negative exome sequencing does not rule out a genetic disorder; instead, it only implies that a genetic diagnosis could not be identified, given the clinical and genetic information available at the time of analysis. Reanalyzing exome data from unsolved cohorts with neurodevelopmental disorders (NDD) holds significant importance for several reasons [1]. Firstly, it allows for the identification of potentially missed or misclassified genetic variants. The initial analysis of exome data may have been limited by the available knowledge at the time, as well as the algorithms and filtering strategies employed. Revisiting the data with improved variant calling algorithms and updated databases can unmask previously concealed genomic variations and lead to the discovery of disease-causing variants that were initially overlooked. Secondly, the reanalysis provides an opportunity to evaluate diagnostic variants according to current standards and guidelines [2]. Over time, our understanding of variant pathogenicity and gene-disease associations evolves, necessitating a reassessment of previously reported variants. By applying updated classification criteria and incorporating additional evidence, such as functional studies or confirmatory publications, the pathogenicity of variants can be more accurately determined. Furthermore, reanalyzing exome data allows for the confirmation or removal of gene-disease associations (GDA). As new research emerges, some previously reported associations may be called into question or require further validation. By critically evaluating the evidence supporting the GDAs, we refine our understanding of the genetic basis of NDD and establish more reliable genotype-phenotype correlations. Lastly, reanalysis can uncover previously unknown gene associations. The constantly expanding knowledge base of gene-disease relationships, with hundreds of new associations being identified each year, provides a valuable resource for revisiting unsolved cohorts. By leveraging this wealth of information and employing advanced computational tools and filtering strategies, researchers can identify novel gene candidates and establish their role in NDD.

Genome Sequencing reveals the impact of non-canonical exon inclusions in rare genetic disease

Uncovering recessive alleles in rare Mendelian disorders by genome sequencing of 174 individuals with monoallelic pathogenic variants

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

The impact of inversions across 33,924 families with rare disease from a national genome sequencing project

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Long-read genome sequencing and variant reanalysis increase diagnostic yield in neurodevelopmental disorders

Identification of synonymous pathogenic variants in monogenic disorders by integrating exome with transcriptome sequencing

Mitochondrial DNA variant detection in over 6,500 rare disease families by the systematic analysis of exome and genome sequencing data resolves undiagnosed cases

Diagnostic genome sequencing improves diagnostic yield: a prospective single-centre study in 1000 patients with inherited eye diseases

Narrowing the Diagnostic Gap: Genomes, Episignatures, Long-Read Sequencing and Health Economic Analyses in an Exome-Negative Intellectual Disability Cohort

Beyond the exome: what's next in diagnostic testing for Mendelian conditions

Unveiling the hidden: revisiting the potential of old genetic data for rare disease research

Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection

Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone

Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease

Long-read sequencing identified a causal structural variant in an exome-negative case and enabled preimplantation genetic diagnosis

Exome copy number variant detection, analysis, and classification in a large cohort of families with undiagnosed rare genetic disease